Biotech isn’t a game for the faint of heart. Most startups walk on stage, strum a few notes, and fade before anyone remembers the name. But every once in a while, you get a group that doesn’t just play, they own the room. Star Therapeutics just proved it with a $125M Series D that brought Sanofi Ventures and Viking Global Investors to the front row. New believers like Janus Henderson Investors, Frazier Life Sciences, and GordonMD Global Investments joined in, while returning heavyweights, Agent Capital, Blue Owl Capital, Catalio, Cormorant, New Leaf, NYBC Ventures, OrbiMed, Qatar Investment Authority, RA Capital, Redmile, Sofinnova, Soleus, and Westlake BioPartners showed up for the encore.
Since launching in 2018, Star Therapeutics has raised over $315M. The current headliner is VGA039, a first-in-class antibody tuned to Protein S, designed as a universal hemostatic therapy. For those not deep in hematology, the stakes are clear: over 50,000 U.S. patients are diagnosed with von Willebrand disease every year, and current options don’t cut it. VGA039 is in pivotal Phase 3 (VIVID-6) with FDA Fast Track and Orphan Drug designations. In a world obsessed with broad pipelines, Star is bending expectations with a pipeline-in-a-product approach.
Their model isn’t smoke and mirrors, it’s engineered. The South San Francisco discovery engine finds shared biology across rare diseases, building antibodies that can attack multiple indications with one program. That’s not just efficiency; it’s portfolio power. Proof? Star already spun out Electra Therapeutics and Vega Therapeutics as independent companies, turning discovery into an ecosystem.
The leadership roster is built for scale. Adam Rosenthal, Ph.D., CEO & founder, cut his teeth at True North Therapeutics and iPierian, both sold for over $700M. Sandip Panicker, Ph.D., drives science as CSO. Gary Patou, M.D., brings hematology expertise as CMO. Scott Robertson balances strategy and finance as CBO/CFO. Michelle Carpenter steers development. Jacob Lai sharpens commercial vision. Monica Kamio anchors HR. Layer in board members like Nancy Stagliano, Beth Seidenberg, Carl Gordon, Jason Hafler, Maha Katabi, Amrit Nagpal, and add Sanofi and Viking on oversight, and you see science and business orbiting in sync.
So what’s next with this $125M raise? Push VGA039 through Phase 3, line up regulatory filings in U.S./EU, and extend clinical reach into Asia. Scale GMP manufacturing. Expand the pipeline. Hire for immunology, rare disease, CMC, regulatory, and commercial muscle. The signal is bigger than the funding; when capital is selective, attracting this syndicate is validation. Star Therapeutics isn’t just raising funds, it’s raising expectations.
